FOXO Research | Milton Maxwell

FOXO

FOXO Technologies Inc.

0.0002

+0.0000+0%

Dec 16, 4:00:00 PM EST

Upcoming Earnings

Report date

≈ -/-

Earnings Call Transcripts

This Quarter (Q1 '26)

No earnings call transcript available yet

Last Quarter (Q4 '25)

No earnings call transcript available

Key Stats

Market Cap

105.30K

P/E (TTM)

Basic EPS (TTM)

-7.13

Dividend Yield

Recent Filings

8-K

FOXO swaps debt for preferred

2/6/26Feb 6, 2026

FOXO Technologies exchanged $200,000 in prior advances from related party Rennova Health for 8,000 shares of Series E Preferred Stock at $25 per share, effective December 31, 2025, but reported February 6, 2026. Debt fully extinguished. Related party deal cleared by disinterested directors as fair.

8-K

Share boost, hospital expansion

1/20/26Jan 20, 2026

FOXO Technologies boosted authorized common shares from 2.5 billion to 10 billion, effective January 18, 2026, to support future needs. Meanwhile, subsidiary Big South Fork Medical Center expanded with inpatient tele-specialty services in cardiology, pulmonology, and nephrology via Rural Physicians Group, plus on-site echocardiography through CompuMed. Fewer transfers. Executives eye higher net revenues.

8-K

Amends preferred stock, boosts shares

12/19/25Dec 19, 2025

FOXO Technologies amended its Series B and C Preferred Stock designations on December 16, 2025, raising the conversion price floor to $0.0001 or 90% of recent VWAP while scrapping mandatory conversion. Majority stockholder—controlled by CEO with 98.6% voting power—approved via written consent boosting authorized Class A Common shares to 10B and Preferred to 20M before April 30, 2026, plus re-electing the full board. Effective 20 days post-mailing.

8-K

CEO's 2025 review

12/16/25Dec 16, 2025

FOXO Technologies CEO Seamus Lagan issued a year-end review on December 15, 2025, highlighting 2025 milestones like Myrtle Recovery's 93% occupancy and 550 projected admissions, Rennova's 7,000+ ER visits, and Vector BioSource's ~$1M revenue outlook. Revenues hit $12M for nine months, eyeing $15M+ full-year, with equity up to $20.2M and debt down to $7.1M. New acquisition vehicle FAC targets growth. NYSE delisting stings.

8-K

Myrtle wins RHA award

12/10/25Dec 10, 2025

FOXO Technologies' Myrtle Recovery Centers earned recognition from the Rural Health Association of Tennessee on December 9, 2025, for community impact after serving patients from 63 counties. Myrtle hit capacity most of 2025. Plans call for expanding facilities and footprint.

About

FOXO Technologies Inc. operates as a healthcare services and technology company in the United States. The company operates through two segments: Healthcare and Labs and Life. The company offers behavioural health; ancillary, including laboratory, radiology, respiratory, and pharmacy; insurance; and other services. The company applies automated machine learning and artificial intelligence (AI) technologies to discover epigenetic biomarkers of human health, wellness, and aging. It offers FOXO Labs, a commercializing proprietary epigenetic biomarker technology enables the adoption of saliva-based health and wellness biomarker solutions for underwriting and risk assessment; and Bioinformatics services that provides data solutions using AI and machine learning for data analysis and processing, and quality checking for academia, healthcare, government, and pharmaceutical research customers. FOXO Technologies Inc. was founded in 2020 and is based in West Palm Beach, Florida.

CEO

Mr. Seamus Lagan

IPO

9/19/2022

Website

https://www.foxotechnologies.com

Employees

102

Sector

Healthcare

Industry

Health Information Services